-
Subject Areas on Research
-
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
-
A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
-
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
-
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
-
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
-
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
-
A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
-
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
-
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
-
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
-
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
-
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
-
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
-
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
-
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
-
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
-
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
-
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
-
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
-
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
-
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
-
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.
-
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
-
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
-
ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
-
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
-
Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
-
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
-
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
-
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
-
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
-
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
-
Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema.
-
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
-
An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.
-
An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone.
-
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
-
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
-
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
-
Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
-
Anti-angiogenic therapy for high-grade glioma.
-
Anti-angiogenic therapy in renal cell cancer.
-
Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
-
Antiangiogenic therapy for high-grade glioma.
-
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
-
Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
-
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
-
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
-
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
-
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
-
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
-
Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma.
-
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
-
Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
-
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
-
Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.
-
Avastin: more questions than answers. .
-
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
-
Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.
-
Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
-
Best practices for treatment of retinal vein occlusion.
-
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
-
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
-
Bevacizumab and daily temozolomide for recurrent glioblastoma.
-
Bevacizumab and everolimus in renal cancer: a rational way forward.
-
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
-
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
-
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
-
Bevacizumab biosimilars: scientific justification for extrapolation of indications.
-
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
-
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
-
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
-
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
-
Bevacizumab for patients with metastatic renal cancer: an update.
-
Bevacizumab for retinopathy of prematurity.
-
Bevacizumab for the treatment of high-grade glioma.
-
Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
-
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
-
Bevacizumab in colorectal cancer.
-
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
-
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
-
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
-
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
-
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
-
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
-
Bevacizumab therapy for glioblastoma: a passionate discussion.
-
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
-
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
-
Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
-
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
-
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
-
Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
-
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.
-
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
-
CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
-
CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes.
-
CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
-
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
-
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
-
Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
-
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
-
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
-
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
-
Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
-
Choroidal neovascularization in a child with infantile primary hyperoxaluria treated with bevacizumab.
-
Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
-
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
-
Colon cancer, version 3.2014.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
-
Combined modality treatment for rectal cancer.
-
Combined-modality therapy for rectal cancer: future prospects.
-
Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
-
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
-
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
-
Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience.
-
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
-
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
-
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
-
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
-
Corneal penetration of topical and subconjunctival bevacizumab.
-
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
-
Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models.
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
-
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
-
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
-
Differences in Presentation and Outcomes in Males and Females With Branch Retinal Vein Occlusion.
-
Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion.
-
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
-
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
-
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
-
Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections.
-
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
-
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
-
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
-
Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma.
-
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
-
Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.
-
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.
-
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
-
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
-
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
-
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
-
Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
-
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
-
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
-
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
-
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
-
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
-
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
-
Endoglin interacts with VEGFR2 to promote angiogenesis.
-
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
-
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
-
Evaluation of hypertension as a marker of bevacizumab efficacy.
-
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.
-
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
-
Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.
-
Eyes With Acute, Treatment-Naïve CRVO and Foveal Intraretinal Hemorrhage: Characteristics and Outcomes.
-
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
-
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
-
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
-
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
-
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
-
Hidden biases in an observational study of bevacizumab beyond progression.
-
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer.
-
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
-
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
-
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
-
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.
-
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
-
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
-
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
-
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
-
Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections.
-
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
-
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
-
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
-
Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.
-
Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
-
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
-
Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
-
Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
-
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
-
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
-
Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration.
-
Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.
-
Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
-
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
-
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
-
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
-
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
-
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.
-
Making genuine progress against metastatic breast cancer.
-
Management of glioblastoma: State of the art and future directions.
-
Management of hearing in pediatric NF2.
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
-
Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
-
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
-
Molecular markers for incidence, prognosis, and response to therapy.
-
Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
-
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
-
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
-
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
-
Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment.
-
New combinations in metastatic colorectal cancer: what are our expectations?
-
Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.
-
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
-
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
-
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
-
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
-
PET concerns in bevacizumab treatment.
-
PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
-
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
-
Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.
-
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
-
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
-
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
-
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
-
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
-
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
-
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
-
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
-
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
-
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
-
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
-
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
-
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
-
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
-
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
-
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
-
Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
-
Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
-
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
-
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
-
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
-
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).
-
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
-
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
-
Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
-
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
-
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
-
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
-
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
-
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
-
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
-
Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
-
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
-
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Quality of life in ICON7: need for patients' perspectives.
-
Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
-
Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
-
Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
-
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
-
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
-
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
-
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
-
Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography.
-
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
-
Recurrent malignant gliomas.
-
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
-
Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
-
Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma.
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
-
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
-
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
-
Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
-
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
-
SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION.
-
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
-
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
-
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
-
Safety of bevacizumab in patients with metastatic breast cancer.
-
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
-
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
-
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
-
Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity.
-
Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
-
Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
-
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
-
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.
-
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
-
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
-
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
-
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
-
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
-
Targeted therapies for cancer 2004.
-
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
-
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.
-
Targeting the future in head and neck cancer.
-
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
-
The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
-
The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
-
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
-
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
-
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
-
The role of targeted therapy in the treatment of colorectal cancer.
-
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
-
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
-
Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity.
-
Topical bevacizumab therapy for corneal neovascularization.
-
Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
-
Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
-
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
-
Treatment of age-related macular degeneration.
-
Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
-
Treatment options in renal cell carcinoma: past, present and future.
-
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
-
Trends in Anti-Vascular Endothelial Growth Factor Agents and Panretinal Photocoagulation Use in Diabetic Retinopathy.
-
Trends in age-related macular degeneration management in Singapore.
-
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
-
Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.
-
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
-
Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
-
Use of bevacizumab in recurrent glioblastoma.
-
VEGF inhibition and renal thrombotic microangiopathy.
-
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
-
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
-
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
-
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
-
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
-
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
-
Keywords of People
-
McCall, Shannon Jones,
Associate Professor of Pathology,
Pathology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Pang, Herbert,
Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Uronis, Hope Elizabeth,
Associate Professor of Medicine,
Medicine, Medical Oncology
-
Zafar, Syed Yousuf,
Adjunct Professor in the Department of Medicine,
Duke Science & Society